Epstein-Barr virus (EBV) is a gamma herpesvirus that causes infectious mononucleosis and is associated with a variety of human lymphoid and epithelial cancers. Immunocompromise is a risk factor for EBV associated disease with malignancies such as post-transplant lymphoproliferative disease arising in transplant patients and central nervous system lymphoma and a proportion of systemic lymphomas being EBV associated in AIDS patients. EBV is also associated with Burkitt' s lymphoma, nasopharyngeal carcinoma, nasal T cell lymphoma, and a subset of Hodgkin' s lymphomas and gastric carcinomas. After primary infection an individual will remain latently infected with EBV and it is this life-long reservoir of latently infected cells that is a factor in the development of subsequent malignant disease. ? ? EBV infection of B cells in culture leads to the outgrowth of immortalized B cell lines and EBNA2 is one of the EBV encoded proteins essential for this process. EBNA2 alters cellular gene expression by targeting a DNA binding protein, CBF1/RBPJk, and switching CBF1 repressed promoters to an activated state. In its targeting of CBF1, EBNA2 mimics activated Notch signaling. A recently recognized ORF present in the EBV BARTs encodes a protein, RPMS, that also interacts with the Notch pathway, in this case negatively regulating Notch activity. The goal of this research program is to understand the contribution of EBNA2 to EBV driven B cell immortalization and the role of RPMS in latency maintainance and in EBV associated epithelial malignancies.
The Specific Aims are: [1] To examine EBNA2 mediated cell survival activities by generating an EBV mutant defective for Nur77 binding and further characterizing the EBNA2-Nur77 interaction and its consequences. [2] To identify and compare the downstream targets of EBNA2 and NotchIC. Primary B cells and EBV negative B cell lines will be infected with lentivirus vectors expressing EBNA2 or NotchIC and with EBV EBNA2 mutant viruses and the changes induced in cell gene expression will determined using gene array technologies. [3] To examine RPMS function and the regulation of RPMS stability. The contribution of phosphorylation to RPMS protein turnover and proteosomal targeting will be examined and the potential role of RPMS anti-Notch activity in epithelial tumor development will be probed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
2R37CA042245-18
Application #
6574042
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Daschner, Phillip J
Project Start
1986-04-01
Project End
2008-01-31
Budget Start
2003-02-10
Budget End
2004-01-31
Support Year
18
Fiscal Year
2003
Total Cost
$367,875
Indirect Cost
Name
Johns Hopkins University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Li, Renfeng; Wang, Leyao; Liao, Gangling et al. (2012) SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function. J Virol 86:5412-21
Zheng, Dasheng; Wan, Jun; Cho, Yong Gu et al. (2011) Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray. J Infect Dis 204:1683-91
Li, Renfeng; Hayward, S Diane (2011) The Ying-Yang of the virus-host interaction: control of the DNA damage response. Future Microbiol 6:379-83
Li, Renfeng; Zhu, Jian; Xie, Zhi et al. (2011) Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 10:390-400
Lo, Angela Kwok Fung; To, Ka Fai; Lo, Kwok Wai et al. (2007) Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 104:16164-9
Martin, Heather J; Lee, Jae Myun; Walls, Dermot et al. (2007) Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 81:9748-58
Farrell, Christopher J; Lee, Jae Myun; Shin, Eui-Cheol et al. (2004) Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc Natl Acad Sci U S A 101:4625-30
Hayward, S Diane (2004) Viral interactions with the Notch pathway. Semin Cancer Biol 14:387-96
Lee, Jae Myun; Lee, Kyoung-Ho; Farrell, Christopher J et al. (2004) EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J Virol 78:12694-7
Smith, P R; de Jesus, O; Turner, D et al. (2000) Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol 74:3082-92

Showing the most recent 10 out of 14 publications